Abdul Mannan – Breaking in Haem: Andexanet Alfa Withdrawn from US Market
Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, shared on LinkedIn:
“Breaking in Haem: Andexanet Alfa Withdrawn from US Market
A major shift in anticoagulation reversal is happening. AstraZeneca is withdrawing the BLA for Andexxa (andexanet alfa), effective Dec 22, 2025.
Why is this happening? Let us make it simple
It’s a case of “Biochemistry vs. Clinical Outcome.”
We failed to bridge the gap from Accelerated Approval (2018) to Traditional Approval.
The Data Dilemma:
Efficacy: It worked. In ANNEXA-4, it slashed anti-Factor Xa activity (e.g., Apixaban levels dropped from ~150 to ~11 ng/mL).
Safety: The ANNEXA-I trial showed a worrying signal. Thrombotic events were 14.6% with Andexanet vs 6.9% with usual care (PCC).
What now?
We return to the basics. For life-threatening bleeding on apixaban or rivaroxaban, we rely on Prothrombin Complex Concentrates (PCC).
A reminder that even ‘targeted’ antidotes must prove they don’t cause more harm than the bleeding they are trying to stop.”
More posts featuring Abdul Mannan on Hemostasis Today.
-
May 7, 2026, 17:31Talha Badar: New Classical Hematology Chapter on Bleeding and Thrombosis
-
May 7, 2026, 17:26Maria Τektonidou: Gene Network Analysis Identifies STAT1 in Thrombotic APS
-
May 7, 2026, 17:23Sonu Bhaskar: Inflammatory Biomarkers in Acute Cerebral Venous Sinus Thrombosis
-
May 7, 2026, 16:53Patricio S. Espinosa: Anticoagulation Is Not an Absolute Contraindication to Amyloid Therapy
-
May 7, 2026, 16:34Arun V J: Give Blood and Be the Hero You Always Wanted to Be
-
May 7, 2026, 16:15August Bones: When Would You Consider Placing an Inferior Vena Cava Filter After a Pulmonary Embolism?
-
May 7, 2026, 15:58Stop Asking Doctors to Do More – Reimagining the Care Team – The US Oncology
-
May 7, 2026, 15:42Chokri Ben Lamine: CVC-Associated UE-DVT and Catheter Removal
-
May 7, 2026, 15:38Samwel Mikaye: Key Insights on Vitamin B12 Deficiency